Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Once-daily roflumilast cream at 0.15% improved symptoms of atopic dermatitis (AD) across multiple end points.
Roflumilast (ALTANA Pharma AG), a phosphodiesterase-4 (PDE4) inhibitor, is being developed for the management of chronic obstructive pulmonary disease (COPD) and asthma. Its once-daily oral ...
Expert Rev Resp Med. 2008;2(5):539-549. Results from human subjects have also demonstrated significant pulmonary anti-inflammatory effects of roflumilast. In a randomized, placebo-controlled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback